rs267607765
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000249.4(MLH1):c.545+1G>A variant causes a splice donor, intron change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★★).
Frequency
Consequence
NM_000249.4 splice_donor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD4 exome Cov.: 29
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
Colorectal cancer, hereditary nonpolyposis, type 2 Pathogenic:1
This variant is considered pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function. This variant is strongly associated with more severe personal and family histories of cancer, typical for individuals with pathogenic variants in this gene [PMID: 27363726]. -
Lynch syndrome Pathogenic:1
Interrupts canonical donor splice site -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in MLH1 are known to be pathogenic. This particular variant has been reported in the literature in individuals affected with Lynch syndrome (PMID: 15849733, 19669161, 20215533, 15879014). Experimental studies have shown that this splice site variant causes exon 6 skipping, leading to a frameshift and premature MLH1 truncation (PMID: 19669161). This sequence change affects a donor splice site in intron 6 of the MLH1 gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.545+1G>A intronic variant results from a G to A substitution one nucleotide after coding exon 6 of the MLH1 gene. This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. This alteration has been reported in an Italian cohort of families meeting Amsterdam criteria (De Felice C et al. Gut, 2005 Sep;54:1279-82). This alteration has also been reported in a German cohort of families meeting Bethesda guidelines or Amsterdam criteria. Study authors reported that RNA analysis revealed an abnormal RT-PCR product with exon 6 skipping (Betz B et al. J Cancer Res Clin Oncol, 2010 Jan;136:123-34). Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at